Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented real-world claims analysis data at ISPOR 2026 that highlights the significant clinical and economic burden of fibromyalgia in U.S. adults. The findings, based on a retrospective analysis of more than 261,000 adult fibromyalgia patients, reveal high rates of comorbidities, extensive healthcare resource utilization, and widespread reliance on multimodal treatment approaches.
According to the data, more than 93% of fibromyalgia patients had at least one fibromyalgia-related comorbidity. Insured patients incurred substantial annual healthcare costs, driven primarily by inpatient services. These findings underscore the unmet need for more effective long-term treatment options as Tonix advances its planned commercial launch of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), the company’s recently approved flagship medicine and the first new treatment for fibromyalgia in more than 15 years.
The real-world evidence presented at ISPOR 2026 is critical for understanding the true impact of fibromyalgia on patients and the healthcare system. Fibromyalgia is a chronic condition characterized by widespread pain, fatigue, and cognitive difficulties, affecting millions of Americans. The high comorbidity rate—over 93%—indicates that fibromyalgia rarely occurs in isolation, often coexisting with conditions such as depression, anxiety, sleep disorders, and other chronic pain syndromes. This complexity drives the need for multimodal treatment approaches, yet many patients continue to experience inadequate symptom control.
The economic burden is equally concerning. The analysis found that healthcare costs for fibromyalgia patients are substantial, with inpatient services being a major cost driver. This suggests that current management strategies may not be effectively preventing disease exacerbations that lead to hospitalizations. For employers and insurers, these costs represent a significant financial strain, highlighting the potential value of more effective therapies that could reduce hospitalizations and improve quality of life.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The presentation of this real-world data at ISPOR 2026 reinforces the urgent need for new treatment options in fibromyalgia. With TONMYA poised to enter the market, Tonix is positioned to address a long-standing gap in care. For more information, visit https://ibn.fm/yMppz or the company’s newsroom at https://ibn.fm/TNXP.
